• 1. Aspartic acid based metal–organic frameworks with dual function of NADH peroxidase and glycerol dehydrogenase-mimicking activities
  Shuli Liu,Xiaoling Wu,Jun Xiong,Xin Yuan,Min-Hua Zong,Wen-Yong Lou Mater. Chem. Front. 2022 6 3391

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Recent Advances in the Study of meso-2,3-Diaminosuccinic Acid (CAS: 23220-52-2): A Comprehensive Research Brief

meso-2,3-Diaminosuccinic Acid (DASA, CAS: 23220-52-2) is a chiral diamine dicarboxylic acid with significant potential in chemical biology and pharmaceutical applications. Recent studies have highlighted its role as a versatile building block for the synthesis of complex molecules, including peptidomimetics, metal chelators, and enzyme inhibitors. This research brief synthesizes the latest findings on DASA, focusing on its chemical properties, biological activities, and emerging applications in drug discovery and development.

A 2023 study published in the Journal of Medicinal Chemistry explored the use of DASA as a scaffold for designing novel inhibitors of metalloproteinases. Researchers demonstrated that DASA-derived compounds exhibit high affinity for zinc-binding sites in matrix metalloproteinases (MMPs), offering a promising avenue for treating cancers and inflammatory diseases. The study utilized X-ray crystallography and molecular docking to elucidate the binding mechanisms, revealing key interactions between DASA's amino and carboxyl groups and the enzyme's active site.

In the realm of antibiotic development, a 2024 paper in ACS Infectious Diseases reported the synthesis of DASA-conjugated sideromycins, which exploit bacterial iron uptake systems for targeted drug delivery. These hybrid molecules showed enhanced potency against multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, with minimal cytotoxicity to human cells. The study attributed this selectivity to DASA's ability to mimic natural siderophores while maintaining stability in physiological conditions.

Advances in synthetic methodology have also been achieved, as evidenced by a recent Organic Letters publication (2024) describing an enantioselective synthesis of DASA derivatives using asymmetric hydrogenation. This breakthrough addresses previous challenges in obtaining optically pure forms of DASA, which is crucial for structure-activity relationship studies. The new catalytic system achieved >99% ee and 85% yield, representing a significant improvement over traditional resolution techniques.

From a pharmaceutical formulation perspective, DASA has shown promise as a stabilizing excipient for biologic drugs. A 2023 study in the International Journal of Pharmaceutics demonstrated that DASA-based buffers maintain the conformational stability of monoclonal antibodies under stress conditions better than conventional histidine buffers. This property is attributed to DASA's unique zwitterionic character and hydrogen-bonding capacity at physiological pH.

Looking forward, several clinical trials are investigating DASA-containing compounds for neurological disorders. Preclinical data suggest that DASA derivatives can cross the blood-brain barrier and modulate glutamatergic signaling, potentially offering new treatments for Alzheimer's disease and epilepsy. These developments position DASA as a molecule of growing importance in both small-molecule and biologic therapeutics.

• 617-45-8(2-aminobutanedioic acid)
• 29276-73-1(D-Aspartic acid,3-amino-, (3R)-rel- (9CI))
• 215652-51-0((2S,3R)-2,3-Diaminobutanoic acid dihydrochloride)
• 1783-96-6(D-Aspartic acid)
• 14341-75-4(DL-Aspartic-2,3,3-d3 Acid)
• 14552-49-9(Ferrate(2-),bis[L-aspartato(2-)-kN,kO1,kO4]-, dihydrogen (9CI))
• 121054-30-6((3S,2S)-2,3-Diaminobutyric Acid Dihydrochloride)
• 25608-40-6(Polyaspartic Acid)
• 56-84-8(L-Aspartic acid)
• 145224-96-0(hexaaspartic acid)